Table 2. Summary estimates of diagnostic criteria and their 95% confidence intervals (95% CI).
Analysis | No. of studies | SEN (95%CI) | SPE (95%CI) | PLR (95%CI) | NLR (95%CI) | DOR (95%CI) | AUC (95%CI) |
Gastric cancer | 47 | 0.77 (0.72–0.80) | 0.81 (0.77–0.84) | 4.0 (3.2–4.9) | 0.29 (0.24–0.36) | 14 (9–20) | 0.86 (0.82–0.88) |
MiRNA profiling | |||||||
Single-miRNA | 39 | 0.75 (0.70–0.79) | 0.80 (0.75–0.84) | 3.7 (2.9–4.6) | 0.32 (0.26–0.39) | 11 (8–17) | 0.84 (0.80–0.87) |
Multiple-miRNAs | 8 | 0.87 (0.75–0.94) | 0.84 (0.75–0.91) | 5.6 (3.1–10) | 0.15 (0.07–0.33) | 37 (10–134) | 0.92 (0.89–0.94) |
Source material | |||||||
Plasma-based | 26 | 0.82 (0.78–0.86) | 0.85 (0.80–0.89) | 5.6 (4.0–7.8) | 0.21 (0.16–0.27) | 27 (16–47) | 0.90 (0.88–0.93) |
Serum-based | 21 | 0.67 (0.61–0.73) | 0.74 (0.69–0.78) | 2.5 (2.1–3.1) | 0.44 (0.37–0.53) | 6 (4–8) | 0.77 (0.73–0.80) |
Colorectal cancer | 47 | 0.73 (0.69–0.77) | 0.80 (0.76–0.83) | 3.6 (3.0–4.2) | 0.34 (0.29–0.39) | 11 (8–14) | 0.83 (0.80–0.86) |
MiRNA profiling | |||||||
Single-miRNA | 29 | 0.68 (0.62–0.73) | 0.77 (0.72–0.81) | 2.9 (2.4–3.5) | 0.42 (0.36–0.50) | 7 (5–10) | 0.79 (0.75–0.82) |
Multiple-miRNAs | 18 | 0.81 (0.77–0.84) | 0.83 (0.79–0.87) | 4.9 (3.8–6.2) | 0.23 (0.19–0.27) | 22 (15–30) | 0.89 (0.86–0.91) |
Source material | |||||||
Plasma-based | 33 | 0.72 (0.65–0.77) | 0.77 (0.73–0.80) | 3.1 (2.5–3.7) | 0.37 (0.30–0.46) | 8 (6–12) | 0.81 (0.77–0.84) |
Serum-based | 14 | 0.77 (0.72–0.81) | 0.85 (0.80–0.89) | 5.1 (3.9–6.7) | 0.28 (0.23–0.33) | 18 (13–26) | 0.88 (0.85–0.90) |
Esophageal cancer | 13 | 0.79 (0.74–0.84) | 0.85 (0.81–0.89) | 5.4 (4.1–7.1) | 0.24 (0.19–0.31) | 22 (14–35) | 0.89 (0.86–0.92) |
All studies | 107 | 0.75 (0.73–0.78) | 0.81 (0.79–0.83) | 4.0 (3.5–4.5) | 0.30 (0.27–0.34) | 13 (10–16) | 0.85 (0.82–0.88) |
CI, confidence interval; SEN, sensitivity; SPE, specificity; PLR, positive likelihood ratio; NLR, negative likelihood ratio; DOR, diagnostic odds ratio; AUC, area under the curve.